Search Results
Your search for 3 matches 14920 pages
Showing 1551 - 1600
IO-Refractory Advanced Renal Cell Carcinoma
This is Part 3 of Treatment Considerations in Renal Cell Carcinoma, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Brian Rini, Pedro Barata, and Kathryn Beckermann discuss the treatment of immunotherapy (IO)-refractory...
Adjuvant Therapy for Renal Cell Carcinoma
This is Part 1 of Treatment Considerations in Renal Cell Carcinoma, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Brian Rini, Pedro Barata, and Kathryn Beckermann discuss the role of adjuvant therapy for renal cell carcinoma...
Incidence and Outcomes of Severe Hepatopathy in National Wilms Tumor Study Protocols
In an analysis of National Wilms Tumor Study (NWTS) protocols reported in the Journal of Clinical Oncology, Oosterom et al identified the incidence of treatment-related severe hepatopathy in patients with Wilms tumor and described outcomes in these patients. Study Details The study involved data...
Academically Developed BCMA-Directed CAR T-Cell Therapy in Relapsed or Refractory Multiple Myeloma
In an interim analysis of a Spanish pilot trial (CARTBCMA-HCB-01) reported in The Lancet Oncology, Oliver-Caldés et al found that an academically developed B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy, ARI0002h, showed activity in patients with relapsed...
Functional Recovery and Quality of Life in Older Patients Undergoing Colorectal Cancer Surgery
In a study of real-world prospective data—GOSAFE—reported in the Journal of Clinical Oncology, Montroni et al found that the majority of patients aged ≥ 70 years undergoing colorectal cancer surgery showed maintained or improved quality of life and achieved functional recovery during follow-up....
Zanidatamab in HER2-Positive Advanced Biliary Tract Cancer
In the phase IIb HERIZON-BTC-01 trial reported in The Lancet Oncology, James J. Harding, MD, and colleagues found that zanidatamab—a bispecific antibody targeting two distinct HER2 epitopes—showed activity in previously treated patients with HER2-positive advanced biliary tract cancer. Study...
Pirtobrutinib After Covalent BTK Inhibitor Treatment in Relapsed or Refractory CLL/SLL
In the phase I/II BRUIN trial reported in The New England Journal of Medicine, Anthony R. Mato, MD, and colleagues found that the noncovalent (reversible) Bruton’s tyrosine kinase (BTK) inhibitor pirtobrutinib exhibited strong activity in patients with relapsed or refractory chronic lymphocytic...
Expert Point of View: Kevin Kalinsky, MD, MS
Session co-moderator Kevin Kalinsky, MD, MS, the Louisa and Rand Glenn Family Chair in Breast Cancer Research, Director of the Glenn Family Breast Center, and Director of Breast Medical Oncology at the Winship Cancer Institute of Emory University, Atlanta, offered his thoughts on PHERGain to The...
PHERGain: Adapted-Response Trial Guides Treatment With Dual HER2 Blockade Alone
The phase II PHERGain trial, which employed a response-adapted strategy in the treatment of early-stage, HER2-positive breast cancer, has shown promising results for the selective use of HER2 blockade and de-escalation of chemotherapy.1 Nearly all patients assigned to skip chemotherapy prior to...
Patients With Prostate Cancer May Face High Rates of Financial Toxicity
About 50% of patients with metastatic prostate cancer may experience financial hardship as a result of their treatment, according to a new study published by Joyce et al in The Journal of Urology. Background "Our most significant finding may be that patients experience financial toxicity despite...
Second-Line Trastuzumab, Ramucirumab, and Paclitaxel in Previously Treated Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer
In a Korean phase Ib/II trial reported in the Journal of Clinical Oncology, Kim et al found that trastuzumab combined with ramucirumab and paclitaxel showed activity in the second-line treatment of patients with HER2-positive advanced gastric or gastroesophageal junction cancer whose disease...
Expert Point of View: Erminia Massarelli, MD, PhD, MS
The invited discussant of the VERSATILE-002 and CUE-101-01 trials, Erminia Massarelli, MD, PhD, MS, said both are examples of a growing interest in evaluating immunotherapeutic strategies and treatment sequences in early-stage head and neck squamous cell cancer as well as in metastatic disease. Dr. ...
Novel HPV-Targeted Agents Boost Efficacy of Pembrolizumab in Head and Neck Cancer, Two Studies Show
Immunotherapeutics that target human papillomavirus (HPV) genotype 16 appear to boost the activity of pembrolizumab in advanced head and neck squamous cell carcinoma. Two examples were presented in posters at the 2023 ASCO Annual Meeting.1,2 The phase II VERSATILE-002 trial evaluated PDS0101,...
Goals of Care in Primary Myelofibrosis
This is Part 3 of Updates in Myeloproliferative Neoplasms, a three-part video roundtable series. In this video, Dr. Naveen Pemmaraju and Dr. Gabriela Hobbs discuss goals of care in primary myelofibrosis. The patient is a 27-year-old woman who presents to the clinic after 6 months of...
I Didn’t Want My Past to Become My Future
When I felt a large mass in my left breast as I was drying off from a shower on Thanksgiving Day, in 2007, I instinctively knew it was cancer. My mother had been diagnosed with breast cancer when she was 38, just 7 years older than I was at the time, and died 4 years later. I was 6 when she was...
Targeting Depressive Symptoms in Younger Breast Cancer Survivors
Guest Editor’s Note: Psychological distress is highly prevalent in women diagnosed with premenopausal breast cancer and has a significant negative impact on their quality of life. Thus, effective strategies are urgently needed to reduce the symptom burden. In this installment of The ASCO Post’s...
Assessing Geriatric Oncology Practice in Portugal
The global population is aging rapidly. Currently, there are more than 703 million people worldwide aged 65 and older, representing 9.1% of the global population. It is estimated that this percentage will grow to 15.9%—1.5 billion people—by 2050.1 And with that growing aging population will come...
Epcoritamab-bysp in Treatment of Relapsed or Refractory B-Cell Lymphomas
On May 19, 2023, epcoritamab-bysp was granted accelerated approval by the U.S. Food and Drug Administration for treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL)–not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two ...
ASCO Updates Guideline on Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer
Results from a series of randomized, controlled trials have prompted an update to the ASCO guideline on venous thromboembolism (VTE) prophylaxis and treatment in patients with cancer. The revised guideline, which had last been updated in 2019, is available from the Journal of Clinical Oncology.1...
How ASCO’s 2023 Breakthrough Meeting Is Putting a Spotlight on Cutting-Edge Advances in Cancer Care Technology and Innovation
After a 4-year hiatus because of the COVID-19 pandemic, ASCO’s Breakthrough meeting is returning to Asia from August 3–5, 2023, in Yokohama, Japan, and will also be livestreamed (https://conferences.asco.org/breakthrough/welcome). Launched in 2019 in Bangkok, Thailand, “Breakthrough is ASCO’s...
Health Systems Strengthening Approach in the United States–Mexico Border Region Improved 5-Year Survival for Children With ALL
The implementation of a collaborative program between North American and Mexican medical institutions to achieve sustainable, high-quality care at a public hospital in the United States–Mexico border region for children with acute lymphoblastic leukemia (ALL) has resulted in significant improvement ...
Second Annual Conference at the Nixon Presidential Library and Museum Emphasizes Patients’ Concerns
On December 23, 1971, President Richard Nixon signed the National Cancer Act of 1971 into law, establishing a national cancer program that included the National Cancer Institute (NCI), other research institutes, and federal and nonfederal programs; funding for 15 new cancer research centers and...
ZUMA-7: Primary Overall Survival Analysis Supports Axicabtagene Ciloleucel as Second-Line Therapy in Advanced Lymphoma
In the primary overall survival analysis of ZUMA-7, second-line treatment with axicabtagene ciloleucel significantly improved overall survival compared with high-dose therapy plus autologous stem cell transplantation (auto-HCT) in patients with early relapsed or refractory large B-cell lymphoma....
A European Leader in Surgical Oncology, Isabel T. Rubio, MD, PhD, Shares Her Story and Sheds Light on the Challenges Ahead
In this installment of The ASCO Post’s Global Oncology series, guest editor Chandrakanth Are, MBBS, MBA, FRCS, FACS, spoke with Isabel T. Rubio, MD, PhD, Head of Breast Surgical Oncology at Clinica Universidad de Navarra, Madrid. Dr. Rubio is active in many societies and is a founding member and...
Expert Point of View: David A. Braun, MD, PhD
David A. Braun, MD, PhD, of Yale Cancer Center, was the formal discussant of the abstract on the 4-year follow-up of the CLEAR trial. “We have made remarkable progress [in advanced renal cell carcinoma] and are now in the combination era of immunotherapy-based therapy and immunotherapy-based...
Addition of Tislelizumab to Chemotherapy Improves Survival in Treatment of Metastatic Esophageal Squamous Cell Carcinoma
As reported in The Lancet Oncology by Jianming Xu, MD, of Fifth Medical Center, Chinese PLA General Hospital, Beijing, corresponding author Harry H. Yoon, MD, of the Department of Oncology, Mayo Clinic, Rochester, and colleagues, an interim analysis of the phase III RATIONALE-306 trial has shown...
Lobular vs Ductal Breast Cancer: Distinctions in Management
As a relatively rare subtype, lobular breast cancer is not well understood by many oncologists. At the 2023 Miami Breast Cancer Conference, Tari A. King, MD, FASCO, described how it differs from its more common counterpart, ductal breast cancer, in terms of characteristics, prognosis, and optimal...
CLEAR Trial: Continued Survival Benefit With First-Line Lenvatinib Plus Pembrolizumab in Advanced Kidney Cancer
At extended follow-up, lenvatinib plus pembrolizumab showed sustained superiority over sunitinib for overall and progression-free survival as first-line treatment for advanced renal cell carcinoma.1 The majority of the benefit was observed in intermediate- and poor-risk subgroups, according to the...
Pathology Assessment During Mastectomy and Overtreatment of the Axilla in Clinically Node-Negative Breast Cancer
Axillary management decisions made during surgery may be associated with aggressive treatment of limited nodal disease, according to data presented at a press briefing at the 2023 American Society of Breast Surgeons Annual Meeting.1 Results of a large National Cancer Database study revealed that...
Expert Point of View: Kohei Shitara, MD and Bradley Alexander McGregor, MD
At the ASCO session on the phase II DESTINY-PanTumor02 trial on T-DXd, the invited discussant, Kohei Shitara, MD, commented: “As expected, this trial demonstrated a very impressive response rate and duration of response” and “showed T-DXd [fam-trastuzumab deruxtecan-nxki] to be a potential new...
DESTINY-PanTumor02: Is T-DXd Heading for Tumor-Agnostic Status?
Fam-trastuzumab deruxtecan-nxki (T-DXd) may prove to be beneficial in a variety of treatment-refractory solid tumors that express HER2, according to findings from the international phase II DESTINY-PanTumor02 trial presented at the 2023 ASCO Annual Meeting.1 For patients with the highest HER2...
SWOG S1826: Nivolumab Plus AVD Surpasses Standard-of-Care Combination Regimen in Patients With Advanced Hodgkin Lymphoma
The addition of nivolumab, an immune checkpoint inhibitor, to chemotherapy significantly improved progression-free survival in adults and children with advanced classical Hodgkin lymphoma with reduced toxicity compared with standard-of-care brentuximab vedotin plus chemotherapy, according to the...
KEYNOTE-671 Trial: Perioperative Pembrolizumab Plus Chemotherapy Improves Outcomes in Stage II and III NSCLC
Neoadjuvant therapy with pembrolizumab plus platinum-based chemotherapy followed by surgery and then adjuvant pembrolizumab led to significantly improved event-free survival in patients with resectable stage II and III non–small cell lung cancer (NSCLC) compared with platinum-based chemotherapy...
Expert Point of View: Ciara L. Freeman, MD, PhD and Asher Chanan-Khan, MD
Ciara L. Freeman, MD, PhD, Assistant Member, Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, Florida, was impressed with the CARTITUDE-4 findings. She said “treaters and patients” will be “watching this space” to see how the results change the...
CARTITUDE-4: Ciltacabtagene Autoleucel Beneficial in Early Myeloma Relapse
Compared with the standard of care for relapsed multiple myeloma, a single infusion of ciltacabtagene autoleucel was associated with a significant 74% reduction in the risk of disease progression in patients with lenalidomide-refractory multiple myeloma after one to three relapses, the phase III...
A Call for Tailored Medical Services in Oncology Care for Older Deaf Patients
My father is deaf. Born deaf, he is now 75 years old. He uses his voice, but he sounds strange to a hearing person when he speaks. He uses lip-reading techniques to communicate. A year ago, he was diagnosed with Hodgkin lymphoma. We did his oncology itinerary together. My father cannot go alone to...
PROSPECT Trial: Pelvic Radiation Therapy Avoided for Most Patients With Intermediate-Risk, Locally Advanced Rectal Cancer
Patients with intermediate-risk rectal cancer who received neoadjuvant chemotherapy with selective use of pelvic chemoradiation therapy had disease-free survival that was noninferior to the standard approach using pelvic chemoradiation, according to findings from the randomized phase III PROSPECT...
Adjuvant Osimertinib Improves Overall Survival in Resectable EGFR-Mutated NSCLC
The phase III ADAURA trial previously found that adjuvant use of osimertinib improved disease-free survival for completely resected EGFR-mutated non–small cell lung cancer (NSCLC) in patients with stage IB, II, or IIIA disease.1 The final analysis of ADAURA, which was presented at the 2023 ASCO...
Intracranial Activity of Adagrasib in Patients With KRAS G12C–Mutated NSCLC and Untreated CNS Metastases
In an analysis reported in the Journal of Clinical Oncology, Negrao et al identified outcomes in the KRYSTAL-1 trial among patients with advanced KRAS G12C–mutated non–small cell lung cancer (NSCLC) who had untreated central nervous system (CNS) metastases at baseline and were treated with...
Association of Alcohol Intake With Risk of Early-Onset Colorectal Cancer
In a Korean study reported in the Journal of Clinical Oncology, Jin et al found that increased alcohol intake may be associated with an increased risk of early-onset colorectal cancer. Study Details The study involved data from 5,666,576 individuals aged 20 to 49 years from the Korean National...
Robotic-Assisted Resection of Challenging Gastric GISTs May Be Safe and Effective
Robot-assisted resection may be safe and effective at removing difficult-to-reach gastric gastrointestinal stromal tumors (GISTs), according to a novel study published by Lwin et al in the Journal of Surgical Research. Background For gastric GISTs, surgery is the standard treatment option; however, ...
First-Line FOLFOXIRI Plus Cetuximab or Bevacizumab in BRAF V600E–Mutant Metastatic Colorectal Cancer
In the German phase II FIRE-4.5 trial reported in the Journal of Clinical Oncology, Stintzing et al found that the addition of cetuximab vs bevacizumab to FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) did not improve objective response rate in the first-line treatment of...
Addition of Neoadjuvant Nivolumab to Platinum-Based Chemotherapy in Stage III NSCLC
In the Spanish phase II NADIM II trial reported in The New England Journal of Medicine, Mariano Provencio, MD, PhD, and colleagues found that the addition of nivolumab to platinum-based chemotherapy improved pathologic complete response (pCR) rates among patients with resectable stage IIIA or IIIB...
Addition of Relacorilant to Nab-paclitaxel in Recurrent, Platinum-Resistant Ovarian Cancer
In a phase II trial reported in the Journal of Clinical Oncology, Nicoletta Colombo, MD, and colleagues found that the selective glucocorticoid receptor modulator relacorilant (given on an intermittent schedule) plus nab-paclitaxel showed benefits vs nab-paclitaxel alone in patients with recurrent, ...
Personalized Dosing May Improve Outcomes in Patients With Prostate Cancer
Physicians may be able to personalize dosing intervals and consequently improve patient outcomes by monitoring early-response biomarkers in patients with prostate cancer who are undergoing treatment with lutetium (Lu)-177–PSMA, according to new findings presented by Emmett et al at the Society of...
First-Line Systemic Treatment Strategies for Initially Unresectable Colorectal Cancer Liver Metastases
In the Dutch Colorectal Cancer Group phase III CAIRO5 study reported in The Lancet Oncology, Bond et al investigated first-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases. The researchers found that FOLFOXIRI (leucovorin, fluorouracil,...
First-Line Enfortumab Vedotin Plus Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer
As reported in the Journal of Clinical Oncology by O’Donnell et al, findings in a cohort of the phase Ib/II EV-103/KEYNOTE-869 study showed durable responses with first-line enfortumab vedotin-ejfv plus pembrolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial...
Comparison of Conditioning Treatments in Patients With AML Undergoing HLA-Haploidentical Hematopoietic Stem Cell Transplant
In a Chinese phase III trial reported in the Journal of Clinical Oncology, Ling et al found that conditioning with busulfan/fludarabine resulted in reduced transplantation-related mortality vs busulfan/cyclophosphamide in patients with acute myeloid leukemia (AML) undergoing human leukocyte antigen ...
TROP-2–Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Advanced NSCLC
In a phase I study (TROPION-PanTumor01) reported in the Journal of Clinical Oncology, Shimizu et al described outcomes with the trophoblast cell-surface antigen 2 (TROP-2)-directed antibody-drug conjugate datopotamab deruxtecan at the dose selected for further development in patients with advanced...
Largest Human Breast Cell Atlas to Date May Offer Insights Into Mammary Biology
Researchers have created the world’s largest and most comprehensive atlas of normal breast tissue—the Human Breast Cell Atlas—which may provide an unprecedented understanding of mammary biology and help identify therapeutic targets for diseases such as breast cancer, according to a recent study...
